Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.

Citation data:

Current therapeutic research, clinical and experimental, ISSN: 0011-393X, Vol: 85, Page: 20-28

Publication Year:
2017
Usage 9
Abstract Views 8
Link-outs 1
Captures 4
Readers 4
Social Media 4
Tweets 4
Citations 1
Citation Indexes 1
PMID:
29158855
DOI:
10.1016/j.curtheres.2017.04.006
Author(s):
Zaily, Dorta Guridi; Marlen, Castellanos Fernandez; Santiago, Dueñas-Carrera; Gillian, Martínez Donato; Carmen, Valenzuela Silva; Zurina, Cinza Estevez; Enrique R, Arús Soler; Liz, Alvarez-Lajonchere; Lisset, González Fabián; Sacha, Lazo Del Vallín; Elena, Ferrer Bataille Show More Hide
Publisher(s):
Elsevier BV
Tags:
Pharmacology, Toxicology and Pharmaceutics; Medicine
Most Recent Tweet View All Tweets
article description
An estimated 170 million individuals worldwide are infected with the hepatitis C virus (HCV). Although treatment options using a combination of pegylated interferon and ribavirin (P-IFN/RBV) are available, sustained clearance of the virus is only achieved in approximately 40% of individuals infected with HCV genotype 1. Recent advances in the treatment of HCV using directly acting antiviral agents have been achieved; however, treatment can be very expensive and is associated with substantial side effects. The development of a new treatment modality is needed. One possible modality could be specific immunotherapy. Terap C is a therapeutic vaccine candidate composed of pIDKE2, a plasmid expressing HCV structural antigens, with a recombinant HCV core protein, Co.120.